GEM Asset Management’s AbbVie ABBV Stock Holding History

GEM Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Sell	4,497 -152	-3%	-$32.7K	0.45%	41
2026 Q1	$1.01M	Buy	4,649 +3	+0.1%	+$665	0.45%	40
2025 Q4	$1.08M	Sell	4,646 -13	-0.3%	-$2.96K	0.48%	38
2025 Q3	$1.08M	Buy	4,659 +4	+0.1%	+$815	0.51%	36
2025 Q2	$873K	Buy	4,655 +18	+0.4%	+$3.35K	0.45%	38
2025 Q1	$956K	Sell	4,637 -17	-0.4%	-$3.31K	0.54%	34
2024 Q4	$827K	Buy	4,654 +27	+0.6%	+$4.96K	0.46%	36
2024 Q3	$896K	Buy	4,627 +3	+0.1%	+$560	0.51%	36
2024 Q2	$793K	Buy	4,624 +3	+0.1%	+$497	0.49%	34
2024 Q1	$759K	Buy	4,621 +3	+0.1%	+$517	0.51%	35
2023 Q4	$716K	Sell	4,618 -196	-4%	-$28.6K	0.5%	34
2023 Q3	$718K	Buy	4,814 +4	+0.1%	+$587	0.57%	32
2023 Q2	$648K	Sell	4,810 -51	-1%	-$7.48K	0.5%	32
2023 Q1	$775K	Sell	4,861 -113	-2%	-$17.3K	0.63%	30
2022 Q4	$804K	Buy	+4,974	New	+$763K	0.69%	27

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GEM Asset Management's ABBV Position: Q2 2026 in Review

GEM Asset Management reduced its AbbVie (ABBV) stake by 3.3% in Q2 2026, selling an estimated $32.7K and leaving 4,497 shares worth $1.13M. The position accounts for 0.45% of the portfolio, ranked #41.

GEM Asset Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

GEM Asset Management held 4,497 shares of AbbVie worth $1.13M as of Q2 2026.
GEM Asset Management sold 152 AbbVie shares in Q2 2026, an estimated $32.7K.
AbbVie made up 0.45% of GEM Asset Management's portfolio in Q2 2026, its #41 holding.
GEM Asset Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on GEM Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.